Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.01 AUD
Change Today +0.001 / 11.11%
Volume 914.0K
As of 7:49 PM 10/4/15 All times are local (Market data is delayed by at least 15 minutes).

avexa ltd (AVX) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/29/14 - A$0.03
52 Week Low
07/30/15 - A$0.0060
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AVEXA LTD (AVX)

Related News

No related news articles were found.

avexa ltd (AVX) Related Businessweek News

No Related Businessweek News Found

avexa ltd (AVX) Details

Avexa Limited, a biotechnology company, is engaged in the research and development, and commercialization of anti-infective pharmaceutical programs and projects for the treatment of human immunodeficiency virus (HIV). The company provides apricitabine, a nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. It also offers Integrase, an anti-retroviral drug; and antibiotics. In addition, the company owns the North Pratt coal mine located in North Pratt, Alabama. Avexa Limited was founded in 2004 and is based in Hawthorn East, Australia.

5 Employees
Last Reported Date: 09/30/15
Founded in 2004

avexa ltd (AVX) Top Compensated Officers

Head of Finance and Financial Controller
Total Annual Compensation: A$152.0K
Head of Drug Development
Total Annual Compensation: A$166.3K
Chief Scientific Officer
Total Annual Compensation: A$202.6K
Compensation as of Fiscal Year 2014.

avexa ltd (AVX) Key Developments

Avexa Ltd. Announces Executive Changes

Arising from the impending realisation of the investment objective of the North Pratt coal mine, Avexa has initiated a search for a Managing Director & CEO. Accordingly, a key focus of the prospective MD/CEO will be to manage this major investment and utilise the funds to drive the commercialisation of ATC. Dr. Jonathan Coates, who has held the dual roles of Interim CEO and CSO for some four years, will retire from the role of Interim CEO with effect from 1 March 2015. During the executive search period, Iain Kirkwood will assume the role of Executive Chairman. Dr. Coates will be retained by Avexa as CSO.

Avexa Ltd. Announces Earnings Results for the Half Year Ended December 31, 2014

Avexa Ltd. announced earnings results for the half year ended December 31, 2014. For the period, revenue from operating activities was up $12,000 (100%) to $12,000. Loss from operating activities was $1,162,000 compared with $1,282,000 for the same period last year. Loss from operations for the period was $780,000 compared with $1,533,000 for the same period last year. Loss from ordinary activities after tax attributable to the members was $780,000 or 0.08 cents diluted per share compared with $1,533,000 or 0.18 cents diluted per share for the same period last year. Net cash used in operating activities was $1,151,000 compared with $765,000 for the same period last year. Acquisition of property, plant and equipement was $2,000 compared with $13,000 for the same period last year. Net tangible assets per ordinary security were 1.2 cents compared to 1.4 cents a year ago. Net assets per ordinary security were 1.2 cents compared to 1.4 cents a year ago.

Avexa Ltd., Annual General Meeting, Nov 24, 2014

Avexa Ltd., Annual General Meeting, Nov 24, 2014., at 11:00 AUS Eastern Standard Time. Location: KPMG, 147 Collins Street. Agenda: To receive and consider the financial report, the directors' report and the auditor's report of Avexa for the financial year ended 30 June 2014; to approve the adoption of remuneration report; to approve the re-election of Director Mr. Iain Kirkwood; to approve the amendment to constitution; and to approve the additional 10% placement facility.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVX:AU A$0.01 AUD +0.001

AVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bristol-Myers Squibb Co $62.23 USD +2.18
Gilead Sciences Inc $98.28 USD +0.01
Merck & Co Inc $50.14 USD +0.77
View Industry Companies

Industry Analysis


Industry Average

Valuation AVX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.2x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEXA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at